These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Exogenous hydrogen sulfide (H Cui X; Liu R; Duan L; Zhang Q; Cao D; Zhang A Biomed Pharmacother; 2023 May; 161():114488. PubMed ID: 37002576 [TBL] [Abstract][Full Text] [Related]
6. Hydrogen sulfide and its donors: Novel antitumor and antimetastatic therapies for triple-negative breast cancer. Li H; Xu F; Gao G; Gao X; Wu B; Zheng C; Wang P; Li Z; Hua H; Li D Redox Biol; 2020 Jul; 34():101564. PubMed ID: 32403079 [TBL] [Abstract][Full Text] [Related]
7. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer. Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628 [TBL] [Abstract][Full Text] [Related]
8. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells. Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795 [TBL] [Abstract][Full Text] [Related]
10. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells. Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276 [TBL] [Abstract][Full Text] [Related]
12. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331 [TBL] [Abstract][Full Text] [Related]
13. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression. Guo GC; Wang JX; Han ML; Zhang LP; Li L Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302 [TBL] [Abstract][Full Text] [Related]
14. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer. Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745 [TBL] [Abstract][Full Text] [Related]
16. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells. Hamurcu Z; Ashour A; Kahraman N; Ozpolat B Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606 [TBL] [Abstract][Full Text] [Related]
17. KR-33028, a potent inhibitor of the Na Amith SR; Wilkinson JM; Fliegel L Biochem Pharmacol; 2016 Oct; 118():31-39. PubMed ID: 27521504 [TBL] [Abstract][Full Text] [Related]
18. H Wu W; Hou CL; Mu XP; Sun C; Zhu YC; Wang MJ; Lv QZ Oxid Med Cell Longev; 2017; 2017():5707830. PubMed ID: 28512525 [No Abstract] [Full Text] [Related]
19. Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p. Li S; Zhou J; Wang Z; Wang P; Gao X; Wang Y Biomed Pharmacother; 2018 Aug; 104():451-457. PubMed ID: 29793177 [TBL] [Abstract][Full Text] [Related]
20. Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells. Hamurcu Z; Delibaşı N; Geçene S; Şener EF; Dönmez-Altuntaş H; Özkul Y; Canatan H; Ozpolat B J Cancer Res Clin Oncol; 2018 Mar; 144(3):415-430. PubMed ID: 29288363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]